CN116492539A - Intelligent control method for artificial pancreas and artificial pancreas system - Google Patents
Intelligent control method for artificial pancreas and artificial pancreas system Download PDFInfo
- Publication number
- CN116492539A CN116492539A CN202310748664.5A CN202310748664A CN116492539A CN 116492539 A CN116492539 A CN 116492539A CN 202310748664 A CN202310748664 A CN 202310748664A CN 116492539 A CN116492539 A CN 116492539A
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- insulin
- mode
- patient
- artificial pancreas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000496 pancreas Anatomy 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 192
- 229940125396 insulin Drugs 0.000 claims abstract description 97
- 102000004877 Insulin Human genes 0.000 claims abstract description 95
- 108090001061 Insulin Proteins 0.000 claims abstract description 95
- 239000008280 blood Substances 0.000 claims abstract description 88
- 210000004369 blood Anatomy 0.000 claims abstract description 88
- 238000001802 infusion Methods 0.000 claims abstract description 47
- 238000012544 monitoring process Methods 0.000 claims abstract description 21
- 230000001174 ascending effect Effects 0.000 claims abstract description 12
- 230000000630 rising effect Effects 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 29
- 239000008103 glucose Substances 0.000 claims description 29
- 230000002641 glycemic effect Effects 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 3
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Abstract
The invention relates to the technical field of insulin control, in particular to an artificial pancreas intelligent control method and an artificial pancreas system; the control method comprises the following steps: setting a basal rate mode and a miniature large-dose mode; judging whether the blood sugar of the patient is in an ascending stage or not; when the blood sugar of the patient is not in the rising stage, starting a basal rate mode; when the blood sugar of the patient is in the rising stage, starting a miniature large-dose mode; the artificial pancreas system comprises a continuous blood sugar monitoring module, an insulin adjusting module and an insulin infusion module, wherein a basal rate mode and a miniature large-dose mode are set, the miniature large-dose mode is selected for insulin infusion when the blood sugar of a patient rises, and the basal rate mode is selected for insulin infusion when the blood sugar of the patient does not rise; the method can avoid the situation that the intake of the carbohydrate is less than that of the actual absorption when the diabetic takes food, so that the blood sugar is increased, and the blood sugar of the diabetic is maintained in a normal range.
Description
Technical Field
The invention relates to the technical field of insulin control, in particular to an artificial pancreas intelligent control method and an artificial pancreas system.
Background
Diabetes is a metabolic disease characterized by hyperglycemia. Hyperglycemia is due to defective insulin secretion or impaired biological action, or both. Long-standing hyperglycemia leads to chronic damage, dysfunction, of various tissues, especially the eyes, kidneys, heart, blood vessels, nerves. Insulin is certainly the best therapeutic technique for the treatment of diabetes. Diabetics therefore need to inject insulin daily to achieve glycemic control. With the continuous development of technology, insulin injection has been transited from injection needles and insulin injection pens to "artificial pancreas", i.e. automatic insulin delivery systems. By integrating an insulin pump with a continuous blood glucose monitor and intelligent application, an immediate insulin infusion dose can be calculated based on the blood glucose level monitored in real time and given for continuous subcutaneous infusion.
However, when a diabetic patient uses an artificial pancreas and ingests food, the amount of carbon in the food is smaller than that actually absorbed by the patient, which results in an increase in blood glucose, the blood glucose of the diabetic patient cannot be maintained in a normal range.
Disclosure of Invention
The invention aims to provide an artificial pancreas intelligent control method and an artificial pancreas system, and aims to solve the technical problems that when a diabetic patient uses an artificial pancreas and ingests food, when the amount of carbon water in the food is smaller than that absorbed by an actual patient, the blood sugar is raised, and the blood sugar of the diabetic patient cannot be maintained in a normal range.
In order to achieve the above purpose, the invention adopts an artificial pancreas intelligent control method, which comprises the following steps:
setting a basal rate mode and a miniature large-dose mode;
judging whether the blood sugar of the patient is in an ascending stage or not;
when the blood sugar of the patient is not in the rising stage, starting a basal rate mode;
when the blood sugar of the patient is in the rising stage, the micro large-dose mode is started.
Wherein, in the step of setting the basic rate mode and the micro high dose mode, the micro high dose mode operates as follows:
predicting the blood sugar of the patient to obtain the current additionally increased insulin;
insulin infusion is performed in large doses using insulin doses at basal rates at future times.
Wherein, in the step of infusing insulin in the form of a bolus dose using the basal rate of insulin at a future time:
the period of time of the future time is set to 0.
Wherein, in the step of setting the basic rate mode and the micro large dose mode, the basic rate mode is operated as follows:
setting a safety threshold;
predicting the blood sugar of a patient to obtain predicted blood sugar at a plurality of time points;
initiating a temporary basal rate until a minimum predicted blood glucose is above a safe threshold;
insulin infusion is performed through the temporary basal rate to regulate blood sugar.
Wherein, in the step of setting the safety threshold value:
safety threshold = lower glycemic target limit-0.5 x 40, where the glycemic target unit is mg/dl.
The invention also provides an artificial pancreas system, comprising the following steps:
the insulin infusion device comprises a continuous blood sugar monitoring module, an insulin adjusting module and an insulin infusion module, wherein the insulin adjusting module is connected with the continuous blood sugar monitoring module, the insulin infusion module is connected with the insulin adjusting module, and the continuous blood sugar monitoring module is connected with the insulin infusion module.
The continuous blood sugar monitoring module is used for continuously monitoring blood sugar of a patient;
the insulin adjusting module is used for judging whether the blood sugar of a patient is in an ascending stage or not, and selecting an insulin infusion mode, wherein the insulin infusion mode comprises a basal rate mode and a miniature large-dose mode;
the insulin infusion module is used for infusing insulin to a patient according to an insulin infusion mode.
According to the artificial pancreas intelligent control method and the artificial pancreas system, a basal rate mode and a miniature large-dose mode are set; judging whether the blood sugar of the patient is in an ascending stage or not; when the blood sugar of the patient is not in the rising stage, starting a basal rate mode; when the blood sugar of the patient is in the rising stage, starting a miniature large-dose mode; setting the continuous blood glucose monitoring module, the insulin adjusting module and the insulin infusion module; by setting the basal rate mode and the miniature large-dose mode, the blood sugar of the patient rises to select the miniature large-dose mode for insulin infusion, and the blood sugar of the patient does not rise to select the basal rate mode for insulin infusion, so that the situation that the intake of carbon water is less than that of actual absorption when a diabetic takes food, and the blood sugar rises is avoided, and the blood sugar of the diabetic is maintained in a normal range.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a flow chart of the steps of the artificial pancreas intelligent control method of the invention.
FIG. 2 is a flowchart illustrating the steps of the micro high dose mode operation of the present invention.
Fig. 3 is a flow chart showing the steps of the basic rate mode operation process of the present invention.
Fig. 4 is a schematic structural view of the artificial pancreas system of the invention.
A 100-continuous blood glucose monitoring module, a 200-insulin regulation module, and a 300-insulin infusion module.
Detailed Description
Referring to fig. 1-3, fig. 1 is a flowchart illustrating steps of an artificial pancreas intelligent control method, fig. 2 is a flowchart illustrating steps of a micro large dose mode operation, and fig. 3 is a flowchart illustrating steps of a basic rate mode operation.
The invention provides an artificial pancreas intelligent control method, which comprises the following steps:
s1: setting a basal rate mode and a miniature large-dose mode;
s2: judging whether the blood sugar of the patient is in an ascending stage or not;
s3: when the blood sugar of the patient is not in the rising stage, starting a basal rate mode;
s4: when the blood sugar of the patient is in the rising stage, the micro large-dose mode is started.
In the embodiment, a basal rate mode and a miniature large-dose mode are set, whether the blood sugar of a patient is in an ascending stage is judged in real time, and when the blood sugar of the patient is not in the ascending stage, the basal rate mode is started to infuse insulin to the patient; when the blood sugar of the patient is in an ascending stage, starting a miniature large-dose mode, and infusing insulin to the patient; by setting the basal rate mode and the miniature large-dose mode, the blood sugar of the patient rises to select the miniature large-dose mode for insulin infusion, and the blood sugar of the patient does not rise to select the basal rate mode for insulin infusion, so that the situation that the intake of carbon water is less than that of actual absorption when a diabetic takes food, and the blood sugar rises is avoided, and the blood sugar of the diabetic is maintained in a normal range.
Further, in the step of setting the basal rate mode and the micro high dose mode, the micro high dose mode operates as follows:
s111: predicting the blood sugar of the patient to obtain the current additionally increased insulin;
s112: insulin infusion is performed in large doses using insulin doses at a basal rate at a future time, with the time period at the future time set to 0.
In this embodiment, the patient's blood glucose is first predicted to obtain the current additional insulin, and insulin infusion is performed in large doses using the insulin dose at the basal rate of the future time, where the time period of the future time is set to 0, such as: the current situation requires an additional 1U of insulin, sets a temporary basal rate of 2U/hour higher than normal, injects the additional insulin for more than 30 minutes, injects the same 1U of additional insulin at 5 minute intervals in a manner of 0.4U,0.3U,0.2U,0.1U, and sets a 0 temporary basal rate of 60 minutes (normal basal rate is 1U/hour) to prevent unnecessary injection of insulin.
Further, in the step of setting the basal rate mode and the micro high dose mode, the basal rate mode operates as follows:
s121: setting a safety threshold value, wherein the safety threshold value=the lower blood sugar target limit-0.5 x 40, and the blood sugar target unit is mg/dl;
s122: predicting the blood sugar of a patient to obtain predicted blood sugar at a plurality of time points;
s123: initiating a temporary basal rate until a minimum predicted blood glucose is above a safe threshold;
s124: insulin infusion is performed through the temporary basal rate to regulate blood sugar.
In this embodiment, a safety threshold is set first, the safety threshold=blood glucose target lower limit-0.5×blood glucose lower limit-0.5×40, wherein the blood glucose target unit is mg/dl, the blood glucose of the patient is predicted, the predicted blood glucose of a plurality of time points is obtained, a temporary basal rate is initiated after the case until the minimum predicted blood glucose is above the safety threshold, insulin infusion is performed through the temporary basal rate, and the blood glucose is regulated.
Referring to fig. 4, fig. 4 is a schematic diagram of the structure of the artificial pancreas system.
The invention also provides an artificial pancreas system, which comprises a continuous blood glucose monitoring module 100, an insulin adjusting module 200 and an insulin delivery injection module 300, wherein the insulin adjusting module 200 is connected with the continuous blood glucose monitoring module 100, the insulin delivery injection module 300 is connected with the insulin adjusting module 200, and the continuous blood glucose monitoring module 100 is connected with the insulin delivery injection module 300.
Further, the continuous blood glucose monitoring module 100 is configured to continuously monitor blood glucose of a patient;
the insulin adjustment module 200 is configured to determine whether the blood glucose of the patient is in an ascending phase, and select an insulin infusion mode, where the insulin infusion mode includes a basal rate mode and a micro-bolus mode;
the insulin infusion module 300 is used to infuse insulin to a patient according to an insulin infusion mode.
In this embodiment, the insulin adjustment module 200 module is connected to the continuous blood glucose monitoring module 100, the insulin infusion module 300 is connected to the insulin adjustment module 200 module, the continuous blood glucose monitoring module 100 is connected to the insulin infusion module 300, the continuous blood glucose monitoring module 100, the insulin adjustment module 200 and the insulin infusion module 300 form a closed loop, wherein the continuous blood glucose monitoring module 100 continuously monitors the blood glucose of the patient, the insulin adjustment module 200 determines whether the blood glucose of the patient is in an ascending phase, an insulin infusion mode is selected, the insulin infusion mode includes a basal rate mode and a micro-large dose mode, and the insulin infusion module 300 infuses insulin to the patient according to the insulin infusion mode.
The above disclosure is only a preferred embodiment of the present invention, and it should be understood that the scope of the invention is not limited thereto, and those skilled in the art will appreciate that all or part of the procedures described above can be performed according to the equivalent changes of the claims, and still fall within the scope of the present invention.
Claims (7)
1. An artificial pancreas intelligent control method is characterized by comprising the following steps:
setting a basal rate mode and a miniature large-dose mode;
judging whether the blood sugar of the patient is in an ascending stage or not;
when the blood sugar of the patient is not in the rising stage, starting a basal rate mode;
when the blood sugar of the patient is in the rising stage, the micro large-dose mode is started.
2. The artificial pancreas intelligent control method according to claim 1, wherein in the step of setting the basal rate mode and the micro bolus mode, the micro bolus mode is operated as:
predicting the blood sugar of the patient to obtain the current additionally increased insulin;
insulin infusion is performed in large doses using insulin doses at basal rates at future times.
3. The artificial pancreas intelligent control method according to claim 2, wherein in the step of performing insulin infusion in the form of a bolus dose using the insulin dose at the future time base rate:
the period of time of the future time is set to 0.
4. The artificial pancreas intelligent control method according to claim 1, wherein in the step of setting the basal rate mode and the micro bolus mode, the basal rate mode operates as follows:
setting a safety threshold;
predicting the blood sugar of a patient to obtain predicted blood sugar at a plurality of time points;
initiating a temporary basal rate until a minimum predicted blood glucose is above a safe threshold;
insulin infusion is performed through the temporary basal rate to regulate blood sugar.
5. The artificial pancreas intelligent control method according to claim 4, wherein, in the step of setting the safety threshold value:
safety threshold = lower glycemic target limit-0.5 x 40, where the glycemic target unit is mg/dl.
6. An artificial pancreas system, for use in an artificial pancreas intelligent control method according to claim 1,
the insulin infusion device comprises a continuous blood sugar monitoring module, an insulin adjusting module and an insulin infusion module, wherein the insulin adjusting module is connected with the continuous blood sugar monitoring module, the insulin infusion module is connected with the insulin adjusting module, and the continuous blood sugar monitoring module is connected with the insulin infusion module.
7. The artificial pancreas system according to claim 6, wherein,
the continuous blood sugar monitoring module is used for continuously monitoring blood sugar of a patient;
the insulin adjusting module is used for judging whether the blood sugar of a patient is in an ascending stage or not, and selecting an insulin infusion mode, wherein the insulin infusion mode comprises a basal rate mode and a miniature large-dose mode;
the insulin infusion module is used for infusing insulin to a patient according to an insulin infusion mode.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310748664.5A CN116492539A (en) | 2023-06-25 | 2023-06-25 | Intelligent control method for artificial pancreas and artificial pancreas system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310748664.5A CN116492539A (en) | 2023-06-25 | 2023-06-25 | Intelligent control method for artificial pancreas and artificial pancreas system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116492539A true CN116492539A (en) | 2023-07-28 |
Family
ID=87325089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310748664.5A Pending CN116492539A (en) | 2023-06-25 | 2023-06-25 | Intelligent control method for artificial pancreas and artificial pancreas system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116492539A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116807464A (en) * | 2023-08-30 | 2023-09-29 | 武汉联影智融医疗科技有限公司 | Blood glucose control method and device based on artificial pancreas system and electronic equipment |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550843A (en) * | 2013-11-08 | 2014-02-05 | 上海移宇科技有限公司 | Skin heating type artificial pancreas |
| CN108245742A (en) * | 2018-01-19 | 2018-07-06 | 苏州英诺迈医学科技服务有限公司 | A kind of insulin injection device |
| CN109999270A (en) * | 2019-03-22 | 2019-07-12 | 北京理工大学 | A kind of adaptive automatic disturbance rejection controller of artificial pancreas based on change of blood sugar trend |
| CN116020001A (en) * | 2021-10-25 | 2023-04-28 | 上海移宇科技股份有限公司 | Closed-loop artificial pancreas insulin infusion control system |
-
2023
- 2023-06-25 CN CN202310748664.5A patent/CN116492539A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550843A (en) * | 2013-11-08 | 2014-02-05 | 上海移宇科技有限公司 | Skin heating type artificial pancreas |
| CN108245742A (en) * | 2018-01-19 | 2018-07-06 | 苏州英诺迈医学科技服务有限公司 | A kind of insulin injection device |
| CN109999270A (en) * | 2019-03-22 | 2019-07-12 | 北京理工大学 | A kind of adaptive automatic disturbance rejection controller of artificial pancreas based on change of blood sugar trend |
| CN116020001A (en) * | 2021-10-25 | 2023-04-28 | 上海移宇科技股份有限公司 | Closed-loop artificial pancreas insulin infusion control system |
Non-Patent Citations (1)
| Title |
|---|
| 黄如彬，周爱儒: "《中国分子糖尿病学》", 中国协和医科大学联合出版社, pages: 350 - 351 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116807464A (en) * | 2023-08-30 | 2023-09-29 | 武汉联影智融医疗科技有限公司 | Blood glucose control method and device based on artificial pancreas system and electronic equipment |
| CN116807464B (en) * | 2023-08-30 | 2024-01-26 | 武汉联影智融医疗科技有限公司 | Blood sugar control device based on artificial pancreas system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4947845A (en) | Method of maximizing catheter longevity in an implantable medication infusion system | |
| Pickup et al. | Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus | |
| CN107715230B (en) | Insulin pump individuation configuration optimization system based on cloud big data | |
| US10166331B2 (en) | Automatic closed-loop control adjustments and infusion systems incorporating same | |
| Mirouze et al. | Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes | |
| US8454576B2 (en) | Device and method for therapy calibration and safety response | |
| CN102836481B (en) | Novel insulin pump | |
| US4911168A (en) | Method of screening and selecting intraperitoneal medication infusion pump candidates | |
| CN116492539A (en) | Intelligent control method for artificial pancreas and artificial pancreas system | |
| US9656020B2 (en) | Glucagon pump controller | |
| CN104756116A (en) | Safeguarding measures for a closed-loop insulin infusion system | |
| CN105169525A (en) | Safeguarding techniques for a closed-loop insulin infusion system | |
| KR100723808B1 (en) | Automatic controlled insulin pump mounted with injection sensor | |
| Mahmud et al. | Evaluation of PD/PID controller for insulin control on blood glucose regulation in a Type-I diabetes | |
| Kritz et al. | Implanted constant basal rate insulin infusion devices for type 1 (insulin-dependent) diabetic patients | |
| Takahashi et al. | A survey of insulin-dependent diabetes—part I: therapies and devices | |
| Matsuo et al. | Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas | |
| KR100723806B1 (en) | Process for controlling the injection of insulin using insulin pump | |
| Galadanci et al. | A closed-loop control strategy for glucose control in artificial pancreas systems | |
| Hu et al. | The design of an intelligent insulin pump | |
| Keen et al. | Aspects of continuous subcutaneous insulin infusion (CSII) in diabetes | |
| Ahmed et al. | Blood glucose-insulin regulation and management system using MATLAB/SIMULINK | |
| Dikondwar | Design and development of insulin delivery system prototype | |
| Renard | Implantable insulin delivery pumps | |
| US20230033205A1 (en) | Automated system for controlling the blood glucose level |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |